We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

XEN1101 for Major Depressive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04827901
Recruitment Status : Recruiting
First Posted : April 1, 2021
Last Update Posted : November 10, 2022
Sponsor:
Collaborators:
Baylor College of Medicine
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
James Murrough, Icahn School of Medicine at Mount Sinai

Tracking Information
First Submitted Date  ICMJE March 30, 2021
First Posted Date  ICMJE April 1, 2021
Last Update Posted Date November 10, 2022
Actual Study Start Date  ICMJE October 19, 2021
Estimated Primary Completion Date January 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 30, 2021)
Change in activation within the reward circuit by fMRI [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
The change in activation within the bilateral ventral striatum (VS) from baseline (week 0) to end of treatment (week 8) as measured by fMRI during an Incentive Flanker Task.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 28, 2021)
  • Change in Montgomery-Åsberg Depression Rating Scale Score [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
    The Montgomery-Åsberg Depression Rating Scale (MADARS) is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 and 60 points, higher score indicating poorer health outcomes. The MADRS provides a measure of the overall level of depression.
  • Change in Quick Inventory of Depressive Symptomatology, Self-Report [QIDS-SR] Score [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
    The Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) is a 16-item self-rated instrument designed to assess the severity of depressive symptoms. The 16 items cover the nine symptom domains of major depression and are rated on a scale of 0-3. Total score ranges from 0 to 27, with ranges of 0-5 (normal), 6-10 (mild), 11-15 (moderate), 16-20 (moderate to severe), and 21+ (severe).
  • Change in Snaith-Hamilton Pleasure Scale (SHAPS) [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
    The Snaith-Hamilton Pleasure Scale (SHAPS) is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity. A total score can be derived by summing the responses to each item. Items answered with "strongly agree" are coded as "1", while a "strongly disagree" response was assigned a score of "4." Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.
  • Change in Temporal Experience of Pleasure Scale [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
    The Temporal Experience of Pleasure Scale (TEPS) is an 18-item self-report measurement of anhedonia which consists of a series of statements that must be rated according to how accurate they are for the individual. The scale produces a sub-score that differentiates the role of anticipatory pleasure ('wanting') and is derived of 10 items. Total scores range is 16-108. Lower scores indicate greater levels of anhedonia.
  • Change in Clinical Global Impression Scale [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
    This is a widely administered clinician rated scale that assesses the subject overall illness severity and the degree of improvement from the initial assessment. Illness severity is rated on a 1-7 scale where 1 corresponds to "Normal, Not at All Ill", 2 is "Borderline Mentally Ill", the anchor for 3 is "Mildly Ill", the anchor for 4 is "Moderately Ill", 5 is "Markedly Ill", 6 is "Severely Ill", and 7 is "Among the Most Extremely Ill Patients". The degree of improvement is rated on a 1-7 scale where 1 corresponds to "Very Much Improved", 2 is "Much Improved", the anchor for 3 is "Minimally Improved", the anchor for 4 is "No Change", 5 is "Minimally Worse", 6 is "Much Worse", and 7 is "Very Much Worse".
Original Secondary Outcome Measures  ICMJE
 (submitted: March 30, 2021)
  • Change in Montgomery-Åsberg Depression Rating Scale Score [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
    The Montgomery-Åsberg Depression Rating Scale (MADARS) is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 and 60 points, higher score indicating poorer health outcomes. The MADRS provides a measure of the overall level of depression.
  • Change in Quick Inventory of Depressive Symptomatology, Self-Report [QIDS-SR] Score [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
    The Quick Inventory of Depressive Symptomatology, Self-Report (QIDS-SR) is a 16-item self-rated instrument designed to assess the severity of depressive symptoms. The 16 items cover the nine symptom domains of major depression and are rated on a scale of 0-3. Total score ranges from 0 to 27, with ranges of 0-5 (normal), 6-10 (mild), 11-15 (moderate), 16-20 (moderate to severe), and 21+ (severe).
  • Change in Snaith-Hamilton Pleasure Scale (SHAPS) [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
    The Snaith-Hamilton Pleasure Scale (SHAPS) is a well-validated 14-item self-report questionnaire commonly used to assess anhedonia. Each item on the SHAPS is worded so that higher scores indicate greater pleasure capacity. A total score can be derived by summing the responses to each item. Items answered with "strongly agree" are coded as "1", while a "strongly disagree" response was assigned a score of "4." Total scores on the SHAPS can range from 14 to 56, with higher scores corresponding to higher levels of anhedonia.
  • Change in Temporal Experience of Pleasure Scale-Anticipatory Subscore [TEPS-ant] [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
    The Temporal Experience of Pleasure Scale (TEPS) is an 18-item self-report measurement of anhedonia which consists of a series of statements that must be rated according to how accurate they are for the individual. The scale produces a sub-score that differentiates the role of anticipatory pleasure ('wanting') and is derived of 10 items. Total scores range is 16-108. Lower scores indicate greater levels of anhedonia.
  • Change in Beck Anxiety Inventory [BAI] Score [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
    The Beck Anxiety Inventory (BAI) is a 21-question multiple-choice self-report inventory that is used for measuring the severity of anxiety. The questions used in this measure ask about common symptoms of anxiety that the subject has had during the past week and takes 5 to 10 minutes to complete. Several studies have found the BAI to be an accurate measure of anxiety symptoms that minimizes the overlap between depression and anxiety scales. The BAI contains 21 questions, each answer being scored on a scale value of 0 ("not at all") to 3 ("severely"), a total score range of 0-63. Higher total scores indicate more severe anxiety symptoms.
  • Change in Clinical Global Impression Scale [ Time Frame: Baseline (week 0), End of treatment (week 8) ]
    This is a widely administered clinician rated scale that assesses the subject overall illness severity and the degree of improvement from the initial assessment. Illness severity is rated on a 1-7 scale where 1 corresponds to "Normal, Not at All Ill", 2 is "Borderline Mentally Ill", the anchor for 3 is "Mildly Ill", the anchor for 4 is "Moderately Ill", 5 is "Markedly Ill", 6 is "Severely Ill", and 7 is "Among the Most Extremely Ill Patients". The degree of improvement is rated on a 1-7 scale where 1 corresponds to "Very Much Improved", 2 is "Much Improved", the anchor for 3 is "Minimally Improved", the anchor for 4 is "No Change", 5 is "Minimally Worse", 6 is "Much Worse", and 7 is "Very Much Worse".
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE XEN1101 for Major Depressive Disorder
Official Title  ICMJE A Proof of Concept Randomized Controlled Trial of XEN1101 for the Treatment of Major Depressive Disorder
Brief Summary This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
This is a phase II, randomized, parallel-arm, placebo-controlled clinical trial were 60 patients with major depressive disorder will be randomized in 1:1 fashion to XEN1101 (N=30) or matching placebo (N=30).
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Major Depressive Disorder
Intervention  ICMJE
  • Drug: XEN1101
    two 10 mg capsules
  • Drug: Placebo
    matching placebo
Study Arms  ICMJE
  • Active Comparator: XEN1101
    Subjects will take two 10 mg capsules of XEN1101 daily for 8 weeks for a total daily dose of 20 mg.
    Intervention: Drug: XEN1101
  • Placebo Comparator: Placebo
    Subjects will take a matching placebo daily for eight weeks.
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 30, 2021)
60
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE February 2024
Estimated Primary Completion Date January 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

  1. Written informed consent (and assent when applicable) obtained from subject
  2. Ability for subject to comply with the requirements of the study as determined by the PI;
  3. Men and women, age 18-65 years;
  4. Participants must meet DSM-5 criteria for current depressive disorder (major depressive disorder [MDD]) in a major depressive episode (MDE) as determined by a study psychiatrist and confirmed using the Structured Clinical Interview for DSM-5 Research Version (SCID-5-RV);
  5. Clinically significant anhedonia as determined by a SHAPS score ≥ 20 at screening;
  6. Current illness severity is at least moderate, defined as a score of ≥4 on the CGI-S Scale;
  7. If female of childbearing potential, must agree to use of a medically accepted form of contraception, or else agree to abstinence until 6 months after the last dose of study drug.

Exclusion Criteria

  1. A primary psychiatric diagnosis other than MDD as defined by DSM-5;
  2. Has a history of schizophrenia or other psychotic disorder, major depressive disorder with psychotic features, or bipolar I or II disorder.
  3. History of non-response to >4 adequate antidepressant trials in the current episode as determined by the Antidepressant Treatment Response Questionnaire (ATRQ);
  4. History of non-response to electroconvulsive therapy in the current depressive episode;
  5. A current diagnosis of depression with peripartum onset;
  6. Diagnosis of a major neurocognitive disorder;
  7. Meets criteria for a substance use disorder within the past 6 months, with the exception of nicotine use disorder;
  8. Patient shows signs of retinal macular disease, or retinal pigment epithelium abnormality prior to randomization.
  9. Male patients, if heterosexually active with partner who is female of childbearing potential, pregnant, or breastfeeding, who are unwilling to agree to barrier contraception for the treatment period and for at least 6 months after the last dose of study drug. Female partners of male participants who are unwilling to use at least one form of highly effective contraception starting at least one cycle prior to male patient study drug initiation until 6 months after the last dose of study drug.
  10. Female participants who are pregnant, breastfeeding, or may become pregnant, or unwilling to practice birth control during participation in the study or the 6 months following;
  11. Inability to swallow capsules;
  12. Any contraindication to MRI including claustrophobia, any trauma or surgery which may have left magnetic material in the body, magnetic implants or pacemakers, and inability to lie still for 1 hour or more;
  13. Positive urine toxicology screen for drugs of abuse at the time of screening*;
  14. Use of any dis-allowed medication according to the study protocol**;
  15. Serious and imminent risk of self-harm or violence as determined by the PI;
  16. Extreme illness severity as defined by a CGI-S score >=6;
  17. Any current active suicidal ideation as measured by a Columbia Suicide Severity Rating Scale [C-SSRS] score of greater than 2 during the past month at the time of screening
  18. History of suicide attempt in past 2 years;
  19. Any unstable medical condition, including as follows; 19.1. History of skin or retinal pigment epithelium abnormalities caused by ezogabine; 19.2. Family history of sudden death of unknown cause; 19.3. Clinically significant abnormalities of laboratory tests, physical examination, or ECG; 19.4. History or presence of long QT syndrome; 19.5. QT corrected by Fridericia's formula (QTcF) > 450 msec; 19.6. Alanine transferase (ALT; SGPT) or aspartate transferase (AST; SGOT) levels >3 times the upper limit of normal (ULN) at screening;
  20. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Sara Hameed, B.A. 212-585-4622 sara.hameed@mssm.edu
Contact: Amelia Karim 212-585-4621 amelia.karim@mssm.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04827901
Other Study ID Numbers  ICMJE GCO 16-0374-02
4R33MH111932-03 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: All of the individual participant data collected during the trial, after deidentification.
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Time Frame: Immediately following publication. No end date.
Access Criteria: Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. Any purpose. Other NDCT Database
URL: https://nda.nih.gov
Current Responsible Party James Murrough, Icahn School of Medicine at Mount Sinai
Original Responsible Party Same as current
Current Study Sponsor  ICMJE James Murrough
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE
  • Baylor College of Medicine
  • National Institute of Mental Health (NIMH)
Investigators  ICMJE
Principal Investigator: James W Murrough, MD, PhD Icahn School of Medicine at Mount Sinai
PRS Account Icahn School of Medicine at Mount Sinai
Verification Date November 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP